Cargando…
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412547/ https://www.ncbi.nlm.nih.gov/pubmed/37558684 http://dx.doi.org/10.1038/s41408-023-00890-y |
| _version_ | 1785086931628982272 |
|---|---|
| author | Miao, Yi Sha, Yeqin Xia, Yi Qin, Shuchao Jiang, Rui Dai, Luomengjia Shen, Hui Qiu, Tonglu Wu, Wei Qiu, Jingyan Yang, Yilian Ding, Chongyang Wu, Yujie Fan, Lei Xu, Wei Li, Jianyong Zhu, Huayuan |
| author_facet | Miao, Yi Sha, Yeqin Xia, Yi Qin, Shuchao Jiang, Rui Dai, Luomengjia Shen, Hui Qiu, Tonglu Wu, Wei Qiu, Jingyan Yang, Yilian Ding, Chongyang Wu, Yujie Fan, Lei Xu, Wei Li, Jianyong Zhu, Huayuan |
| author_sort | Miao, Yi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10412547 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104125472023-08-11 Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort Miao, Yi Sha, Yeqin Xia, Yi Qin, Shuchao Jiang, Rui Dai, Luomengjia Shen, Hui Qiu, Tonglu Wu, Wei Qiu, Jingyan Yang, Yilian Ding, Chongyang Wu, Yujie Fan, Lei Xu, Wei Li, Jianyong Zhu, Huayuan Blood Cancer J Correspondence Nature Publishing Group UK 2023-08-09 /pmc/articles/PMC10412547/ /pubmed/37558684 http://dx.doi.org/10.1038/s41408-023-00890-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Miao, Yi Sha, Yeqin Xia, Yi Qin, Shuchao Jiang, Rui Dai, Luomengjia Shen, Hui Qiu, Tonglu Wu, Wei Qiu, Jingyan Yang, Yilian Ding, Chongyang Wu, Yujie Fan, Lei Xu, Wei Li, Jianyong Zhu, Huayuan Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort |
| title | Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort |
| title_full | Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort |
| title_fullStr | Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort |
| title_full_unstemmed | Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort |
| title_short | Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort |
| title_sort | ibrutinib plus fludarabine, cyclophosphamide and rituximab (ifcr) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without tp53 aberrations: a prospective real-world study in chinese cohort |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412547/ https://www.ncbi.nlm.nih.gov/pubmed/37558684 http://dx.doi.org/10.1038/s41408-023-00890-y |
| work_keys_str_mv | AT miaoyi ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT shayeqin ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT xiayi ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT qinshuchao ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT jiangrui ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT dailuomengjia ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT shenhui ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT qiutonglu ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT wuwei ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT qiujingyan ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT yangyilian ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT dingchongyang ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT wuyujie ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT fanlei ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT xuwei ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT lijianyong ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort AT zhuhuayuan ibrutinibplusfludarabinecyclophosphamideandrituximabifcrasinitialtreatmentinchroniclymphocyticleukemiasmalllymphocyticleukemiawithorwithouttp53aberrationsaprospectiverealworldstudyinchinesecohort |